SiRNA‐mediated down‐regulation of SEZ6L2 prevents phosphorylation of adducin and neuritogenesis.19 Higher SEZ6L2 expression predicts a poor prognosis for NSCLC, but the function of SEZ6L2 in cancer was still unclear.12 In this study, the in vitro and in vivo results suggested that SEZ6L2 functioned as an oncogene in CRC. The gene discussed is SEZ6L2; the disease is colorectal carcinoma.